Table 3. mtDNAcn in peripheral blood leukocytes and disease progression among localized prostate cancer patients who received active treatments.
| mtDNAcn | Progression N (%) |
No Progression N (%) |
Crude HR (95% CI) | P value | Adjusted HRa (95% CI) | P value |
|---|---|---|---|---|---|---|
| 3rd tertile (highest) | 35 (8.0) | 401 (92.0) | Reference | N/A | Reference | N/A |
| 2nd and 1st tertile | 104 (12.5) | 726 (87.5) | 1.59 (1.09–2.34) | 0.02 | 1.56 (0.96–2.54) | 0.07 |
a
Adjusted for age, BMI, smoking status, pack-year, D'Amico risk groups, and initial primary treatment
Abbreviations: mtDNAcn, mitochondrial DNA copy number; HR, hazard ratio; CI, confidence interval